Search results
Results from the WOW.Com Content Network
Atomoxetine, formerly sold under the brand name Strattera [12], is a selective norepinephrine reuptake inhibitor (sNRI) medication used to treat attention deficit hyperactivity disorder (ADHD) [13] and, to a lesser extent, cognitive disengagement syndrome (CDS).
Attention deficit hyperactivity disorder management options are evidence-based practices with established treatment efficacy for ADHD.Approaches that have been evaluated in the management of ADHD symptoms include FDA-approved pharmacologic treatment and other pharmaceutical agents, psychological or behavioral approaches, combined pharmacological and behavioral approaches, cognitive training ...
t 1/2: Biological half-life; Atomoxetine. The pharmacokinetics of atomoxetine are similar in children, teenagers and adults. Pharmacokinetics of atomoxetine has not been studied in children younger than 6 years old. Pharmacokinetic studies have shown that atomoxetine capsules and oral solutions are equivalent.
Stelazine (trifluoperazine) – an antipsychotic used in the treatment of psychotic disorders, anxiety, and nausea caused by chemotherapy [2] Strattera (atomoxetine) – a non-stimulant medication used to treat ADHD; Suboxone (buprenorphine/naloxone) - a partial opioid agonist used in the treatment of opioid use disorder
The half-life of desvenlafaxine is about 11 hours, and steady-state concentrations are achieved after 4 to 5 days. [58] The half-life of duloxetine is about 12 hours (range: 8–17 hours), and steady-state is achieved after about 3 days. [11] Milnacipran has a half-life of about 6 to 8 hours, and steady-state levels are reached within 36 to 48 ...
Lisdexamfetamine, sold under the brand names Vyvanse and Elvanse among others, is a stimulant medication that is used to treat attention deficit hyperactivity disorder (ADHD) in children and adults and for moderate-to-severe binge eating disorder in adults. [16]
This is a complete list of clinically approved prescription antidepressants throughout the world, as well as clinically approved prescription drugs used to augment antidepressants or mood stabilizers, by pharmacological and/or structural classification.
Paroxetine may produce discontinuation-related symptoms at a greater rate than other SSRIs, though qualitatively similar effects have been reported for all SSRIs. [181] [182] Discontinuation effects appear to be less for fluoxetine, perhaps owing to its long half-life and the natural tapering effect associated with its slow clearance from the ...